Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
APLT Stock Forecast 2025-2026
$0.32
Current Price
$45.30M
Market Cap
Buy 2
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to APLT Price Targets
+3,962.5%
To High Target of $13.00
+1,150.0%
To Median Target of $4.00
+368.8%
To Low Target of $1.50
APLT Price Momentum
0.0%
1 Week Change
-13.5%
1 Month Change
-93.4%
1 Year Change
-62.8%
Year-to-Date Change
-97.0%
From 52W High of $10.62
+8.5%
From 52W Low of $0.29
📊 TOP ANALYST CALLS
Did APLT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Applied Therapeutics is one of their latest high-conviction picks.
Latest APLT Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, APLT has a neutral consensus with a median price target of $4.00 (ranging from $1.50 to $13.00). Currently trading at $0.32, the median forecast implies a 1,150.0% upside. This outlook is supported by 2 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yigal Nochomovitz at Citigroup, projecting a 3,962.5% upside. Conversely, the most conservative target is provided by Brian Abrahams at RBC Capital, suggesting a 368.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
APLT Analyst Ratings
2
Buy
2
Hold
0
Sell
APLT Price Target Range
Low
$1.50
Average
$4.00
High
$13.00
Current: $0.32
Latest APLT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for APLT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Reiterates | $1.50 |
| Dec 23, 2024 | William Blair | Sami Corwin | Market Perform | Downgrade | $0.00 |
| Dec 20, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $1.50 |
| Dec 2, 2024 | UBS | Esther Rajavelu | Neutral | Downgrade | $2.00 |
| Nov 29, 2024 | Baird | Brian Skorney | Outperform | Maintains | $5.00 |
| Nov 29, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $8.00 |
| Nov 29, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Downgrade | $4.00 |
| Nov 27, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $13.00 |
| Sep 19, 2024 | Leerink Partners | Joseph Schwartz | Outperform | Maintains | $14.00 |
| Sep 19, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $11.00 |
| Aug 27, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $8.00 |
| Jul 31, 2024 | William Blair | Tim Lugo | Outperform | Initiates | $0.00 |
| Jul 17, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $12.00 |
| Apr 11, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $12.00 |
| Mar 26, 2024 | RBC Capital | Brian Abrahams | Outperform | Initiates | $12.00 |
| Mar 15, 2024 | UBS | Esther Rajavelu | Buy | Maintains | $13.00 |
| Mar 6, 2024 | UBS | Esther Rajavelu | Buy | Maintains | $12.00 |
| Feb 22, 2024 | Leerink Partners | Joseph Schwartz | Outperform | Initiates | $12.00 |
| Feb 16, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $7.00 |
| Apr 25, 2023 | Baird | Brian Skorney | Outperform | Maintains | $14.00 |
Applied Therapeutics Inc. (APLT) Competitors
The following stocks are similar to Applied Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
APLT
Applied Therapeutics
mkt cap
45.30M
Applied Therapeutics Inc. (APLT) Financial Data
Applied Therapeutics Inc. has a market capitalization of $45.30M with a P/E ratio of 0.0x. The company generates $265,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -41,030.6% and return on equity of -83.7%.
Valuation Metrics
Market Cap
$45.30M
Enterprise Value
$-4,017,853
P/E Ratio
0.0x
PEG Ratio
-0.7x
Price/Sales
171.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-41,030.6%
Net Margin
0.0%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+112.2%
Current Ratio
3.0x
Debt/Equity
7.4x
ROE
-83.7%
ROA
-65.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Applied Therapeutics Inc. (APLT) Business Model
About Applied Therapeutics Inc.
What They Do
Develops treatments for unmet medical needs.
Business Model
Applied Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on innovative therapies for rare metabolic and inflammatory diseases. The company generates revenue through the development and commercialization of its drug candidates, specifically targeting conditions such as Galactosemia and Sorbitol dehydrogenase deficiency.
Additional Information
Headquartered in New York City, Applied Therapeutics is dedicated to advancing treatment options for orphan diseases, potentially improving health outcomes for patients. The company's commitment to research and development positions it as a key player in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
36
CEO
Mr. Les D. Funtleyder
Country
United States
IPO Year
2019
Website
www.appliedtherapeutics.comApplied Therapeutics Inc. (APLT) Latest News & Analysis
Latest News
Quick Summary
Applied Therapeutics, Inc. announced the promotions of Evan Bailey to Chief Medical Officer and Dottie Caplan to Executive Vice President of Patient Advocacy and Government Affairs, effective June 15, 2025.
Why It Matters
Leadership changes at Applied Therapeutics may signal strategic shifts, impacting the company's direction and potentially affecting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Applied Therapeutics reported 24-month results from the INSPIRE trial for govorestat, showing reduced sorbitol levels and improved outcomes in CMT-SORD patients. NDA submission expected in 2025.
Why It Matters
Positive clinical trial results for govorestat in treating CMT-SORD may enhance investor confidence. Statistically significant outcomes and a potential NDA submission could lead to future revenue growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The company will present full 12-month clinical data and new topline 18-month and 24-month results from the Phase 3 INSPIRE trial of govorestat for CMT-SORD at the 2025 Peripheral Nerve Society Meeting.
Why It Matters
The presentation of new clinical data for govorestat may influence investor sentiment, impacting stock prices and potential market value based on trial outcomes in CMT-SORD.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A late-breaking presentation will share full 12-month clinical data from the INSPIRE Phase 3 trial, along with topline 18-month and 24-month data prior to the open-label extension.
Why It Matters
The presentation of detailed clinical trial data can influence stock prices, indicating potential approval or market success of the product, impacting investor sentiment and future revenue projections.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors can reach out to a law firm at no charge to explore options for recovering their financial losses.
Why It Matters
The offer of no-cost legal consultation indicates potential for collective investor action, which could influence stock prices and market sentiment regarding the involved company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Applied Therapeutics (Nasdaq: APLT) has filed a Form 12b-25 for a 15-day extension to submit its 2024 Annual Report (Form 10-K), now expected by April 15, 2025.
Why It Matters
A late filing of the 10-K report may signal financial issues or operational delays, potentially affecting investor confidence and stock performance for Applied Therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About APLT Stock
What is Applied Therapeutics Inc.'s (APLT) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Applied Therapeutics Inc. (APLT) has a median price target of $4.00. The highest price target is $13.00 and the lowest is $1.50.
Is APLT stock a good investment in 2026?
According to current analyst ratings, APLT has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for APLT stock?
Wall Street analysts predict APLT stock could reach $4.00 in the next 12 months. This represents a 1,150.0% increase from the current price of $0.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Applied Therapeutics Inc.'s business model?
Applied Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on innovative therapies for rare metabolic and inflammatory diseases. The company generates revenue through the development and commercialization of its drug candidates, specifically targeting conditions such as Galactosemia and Sorbitol dehydrogenase deficiency.
What is the highest forecasted price for APLT Applied Therapeutics Inc.?
The highest price target for APLT is $13.00 from Yigal Nochomovitz at Citigroup, which represents a 3,962.5% increase from the current price of $0.32.
What is the lowest forecasted price for APLT Applied Therapeutics Inc.?
The lowest price target for APLT is $1.50 from Brian Abrahams at RBC Capital, which represents a 368.8% increase from the current price of $0.32.
What is the overall APLT consensus from analysts for Applied Therapeutics Inc.?
The overall analyst consensus for APLT is neutral. Out of 9 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are APLT stock price projections?
Stock price projections, including those for Applied Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 7, 2025 2:13 AM UTC